Open Access

Effects of long‑term scopolamine treatment on cognitive deficits and calcium binding proteins immunoreactivities in the mouse hippocampus

  • Authors:
    • Ji Hyeon Ahn
    • Bai Hui Chen
    • Bing Chun Yan
    • Joon Ha Park
    • Il Jun Kang
    • Tae‑Kyeong Lee
    • Jeong Hwi Cho
    • Bich‑Na Shin
    • Jae‑Chul Lee
    • Yong Hwan Jeon
    • Seongkweon Hong
    • Young Joo Lee
    • Soo Young Choi
    • Moo‑Ho Won
  • View Affiliations

  • Published online on: October 27, 2017     https://doi.org/10.3892/mmr.2017.7928
  • Pages: 293-299
  • Copyright: © Ahn et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

GABAergic projections terminate on numerous hippocampal interneurons containing calcium binding proteins (CBPs), including calbindin D‑28k (CB), calretinin (CR) and parvalbumin (PV). Memory deficits and expression levels of CB, CR, and PV were examined in the hippocampal subregions following systemic scopolamine (Scop; 1 mg/kg) treatment for 4 weeks in mice. Scop treatment induced significant memory deficits from 1 week after Scop treatment. CB, CR and PV immunoreactivities distributions were in hippocampal subregions [CA1 and CA3 regions, and the dentate gyrus (DG)]. CB immunoreactivity (CB+) was gradually decreased in all subregions until 2 weeks after Scop treatment, and CB+ was decreased to the lowest level in all subregions at 3 and 4 weeks. CR+ in the CA1 region was gradually decreased until 2 weeks and hardly observed at 3 and 4 weeks; in the CA3 region, CR+ was not altered in all subregions at any time. In the DG, CR+ was gradually decreased until 2 weeks and lowest at 3 and 4 weeks. PV+ in the CA1 region was not altered at 1 week, and gradually decreased from 2 weeks. In the CA3 region, PV+ did not change in any subregions at any time. In the DG, PV+ was not altered at 1 week, decreased at 2 weeks, and lowest at 3 and 4 weeks. In brief, Scop significantly decreased CBPs expressions in the hippocampus ≥3 weeks after the treatment although memory deficits had developed at 1 week. Therefore, it is suggested that Scop (1 mg/kg) must be systemically treated for ≥3 weeks to investigate changes in expression levels of CBPs in the hippocampus.
View Figures
View References

Related Articles

Journal Cover

January-2018
Volume 17 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ahn J, Chen B, Yan B, Park J, Kang I, Lee TK, Cho J, Shin BN, Lee JC, Jeon Y, Jeon Y, et al: Effects of long‑term scopolamine treatment on cognitive deficits and calcium binding proteins immunoreactivities in the mouse hippocampus. Mol Med Rep 17: 293-299, 2018
APA
Ahn, J., Chen, B., Yan, B., Park, J., Kang, I., Lee, T. ... Won, M. (2018). Effects of long‑term scopolamine treatment on cognitive deficits and calcium binding proteins immunoreactivities in the mouse hippocampus. Molecular Medicine Reports, 17, 293-299. https://doi.org/10.3892/mmr.2017.7928
MLA
Ahn, J., Chen, B., Yan, B., Park, J., Kang, I., Lee, T., Cho, J., Shin, B., Lee, J., Jeon, Y., Hong, S., Lee, Y., Choi, S., Won, M."Effects of long‑term scopolamine treatment on cognitive deficits and calcium binding proteins immunoreactivities in the mouse hippocampus". Molecular Medicine Reports 17.1 (2018): 293-299.
Chicago
Ahn, J., Chen, B., Yan, B., Park, J., Kang, I., Lee, T., Cho, J., Shin, B., Lee, J., Jeon, Y., Hong, S., Lee, Y., Choi, S., Won, M."Effects of long‑term scopolamine treatment on cognitive deficits and calcium binding proteins immunoreactivities in the mouse hippocampus". Molecular Medicine Reports 17, no. 1 (2018): 293-299. https://doi.org/10.3892/mmr.2017.7928